Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies
Immunovant Q3 net loss smaller than expected
Brief: Immunovant Q3 Net Income USD -110.635 Million Vs. IBES Estimate USD -125.1 Million
Brief: Immunovant Announces Pricing Of $550 Million Common Stock Financing
Autoimmune drugmaker Immunovant's Q2 net loss misses estimates
U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech
U.S. RESEARCH ROUNDUP- Advanced Drainage Systems, Assurant, Chipotle Mexican Grill
Brief: Immunovant Q1 Net Income USD -120.613 Million
Immunovant Inc reports results for the quarter ended March 31 - Earnings Summary
Immunovant Inc expected to post a loss of 72 cents a share - Earnings Preview
Brief: Immunovant Announces Next Phase Of Growth With Roivant Including Changes To Its Leadership Team And Additional Indications
Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate
U.S. STOCKS ON THE MOVE-Gilead Sciences, Plug Power, BGM Group
U.S. STOCKS ON THE MOVE-Gilead Sciences, Plug Power, BGM Group
Immunovant falls after UBS says late-stage data for muscle disorder drug 'underwhelms'
Brief: Roivant Sciences Says Phase 3 MG Study Meets Primary Endpoint
Immunovant's muscle disorder treatment meets main goal in late-stage trial (updated)
Immunovant's muscle disorder treatment meets main goal in late-stage trial